SUBSCRIBE: Print / eNewsletter
Preserving Fertility in BRCA-Positive Breast Cancer
In this interview we discuss a recent study presented at ESMO on fertility-preserving procedures for women with BRCA-positive breast cancers
David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer
In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.
Periodontal Disease Linked to Certain Cancer Types
In this interview we discuss a recent study that linked periodontal disease with an increased cancer risk, specifically melanoma and cancers of the lung, breast, esophagus, and gallbladder.
New ASCO Guideline on Second-Line Hormone Therapy in Prostate Cancer
In this interview we discuss the ASCO provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer.
Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma
In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin.
Does WBRT Still Have a Role for Cancer Patients With Brain Metastases?
In this interview we discuss new data on the use of radiotherapy in cancer patients with brain metastases.
Role of Gut Microbiome in Metastatic Melanoma Patients on Immunotherapy
In this interview we discuss the effect of the gut microbiome on responses and survival outcomes in metastatic melanoma patients treated with anti–PD-1 immunotherapies.
Treatment Options and Course of Action in Relapsed Multiple Myeloma
In this interview we discuss how relapse in multiple myeloma manifests and treatment options for relapsed/refractory patients.
Homologous Recombination Deficiency and PARP Inhibition in Ovarian Cancer
As part of our coverage of the 2017 ASCO Annual Meeting, we discuss homologous recombination deficiency in ovarian cancer and PARP inhibitors.
TKI Discontinuation Possible for Some CML Patients
Ahead of the 2017 ASCO Annual Meeting, we discuss the discontinuation of TKIs in some chronic myeloid leukemia patients.